Indymedia Global Features
- 2012-05-23 05:29:00
Indymedia Global Features
- 2012-05-23 04:23:00
Indymedia Global Features
- 2012-05-23 04:23:00
Voltaire
- 2012-05-23 01:40:50
Indymedia Global Features
- 2012-05-23 01:38:00
(...) “Advances in cannabinoid science over the past 16 years have given rise to a wealth of new opportunities for the development of medically useful cannabinoid-based drugs. The accumulated data suggest a variety of indications, particularly for pain relief, antiemesis, and appetite stimulation. For patients who suffer simultaneously from severe pain, nausea, and appetite loss, such as those with AIDS or who are undergoing chemotherapy, cannabinoid drugs might offer broad-spectrum relief not found in any other single medication”. (...) “the report concludes that the future of cannabinoid drugs lies not in smoked marijuana but in chemically defined drugs that act on the cannabinoid systems that are a natural component of human physiology. Until such drugs can be developed and made available for medical use, the report recommends interim solutions”.
John A. Benson, Jr., and Stanley J. Watson, Jr.
Co-principal investigators:
Marijuana and Medicine - Preface.
Contents
Executive Summary, 1
1. Introduction, 13
How This Study Was Conducted, 15
Marijuana Today, 16
Marijuana and Medicine, 19
Who Uses Medical Marijuana? 20
Cannabis and the Cannabinoids, 24
Organization of the Report, 30
2. Cannabinoids and Animal Physiology, 33
Introduction, 33
Cannabinoid Receptors, 39
The Endogenous Cannabinoid System, 43
Sites of Action, 48
Cannabinoid Receptors and Brain Functions, 51
Chronic Effects of THC, 56
Cannabinoids and the Immune System, 59
Conclusions and Recommendations, 69
3. First, Do No Harm: Consequences of Marijuana Use and Abuse, 83
The Marijuana ’’High’’, 83
Drug Dynamics, 84
Marijuana Use and Dependence, 92
Link Between Medical Use and Drug Abuse, 101
Psychological Harms, 104
Physiological Harms: Tissue and Organ Damage, 109
Summary and Conclusions, 125
4. The Medical Value Of Marijuana and Related Substances, 137
Standards for Evaluating Clinical Trials, 138
Analgesia, 139
Nausea and Vomiting, 145
Wasting Syndrome and Appetite Stimulation, 154
Neurological Disorders, 159
Glaucoma, 173
Summary, 177
Other Reports on Marijuana as Medicine, 180
5. Development of Cannabinoid Drugs, 193
Federal Drug Development Policy, 194
Development and Marketing of Marinol, 202
Market Outlook for Cannabinoids, 208
Regulation of and Market Outlook for Marijuana, 213
Conclusions, 218
Appendixes
A. Individuals and Organizations That Spoke or Wrote to the Institute of Medicine About Marijuana and Medicine, 225
B. Workshop Agendas, 232
C. Scheduling Definitions, 240
D. Statement of Task, 242
E. Recommendations Made in Recent Reports on the Medical Use of Marijuana, 244
F. Rescheduling Criteria, 256
Index, 259
(24 de setiembre de 2010)
Todos los derechos reservados. Prohibida la reproducción parcial o total de estos contenidos con fines comerciales y/o lucrativos. Se permite la reproducción siempre que se cite la autoría, se haga referencia a www.herbogeminis.com y se notifique por correo electrónico dicha reproducción.